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AObjective:We intended to define the role of the National Institutes of Health Stroke Scale and the Mini-Mental
State Examination in identifying adverse neurologic outcomes in a large international sample of patients under-
going cardiac surgery.
Methods:We evaluated 4707 patients undergoing cardiac surgery with cardiopulmonary bypass at 72 centers in
17 countries between November 1996 and June 2000. Prespecified overt neurologic outcomes were categorized
as type I (clinically diagnosed stroke, transient ischemic attack, encephalopathy, or coma) or type II (deterioration
of intellectual function). The National Institutes of Health Stroke Scale and Mini-Mental State Examination were
administered preoperatively and on postoperative day 3, 4, or 5. Receiver operating characteristic curves were
plotted to determine the predictive value of worsening in National Institutes of Health Stroke Scale and Mini-
Mental State Examination scores with respect to type I and II outcomes.
Results: The receiver operating characteristic area under the curve for changes in National Institutes of Health
Stroke Scale score (n ¼ 4620) was 0.89 for type I outcomes and 0.66 for type II outcomes. A 1-point worsening
in National Institutes of Health Stroke Scale score provided excellent discrimination (86% specificity; 84%
sensitivity) of type I outcomes. The receiver operating characteristic area under the curve for changes in Mini-
Mental State Examination score (n¼ 4707) was 0.75 for type I outcomes and 0.71 for type II outcomes. A 2-point
worsening in Mini-Mental State Examination score provided only fair discrimination (73% specificity; 62%
sensitivity) of type II outcomes.
Conclusion:We used baseline controls and postoperative worsening in National Institutes of Health Stroke Scale
and Mini-Mental State Examination scores to predict both serious adverse neurologic outcome and deterioration
of intellectual function. Our findings provide the only reference for evaluating these tests that are used in cardiac
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The Journal of Thoracic and CaTheNational Institutes ofHealth Stroke Scale (NIHSS) is used
to evaluate neurologic impairment. It was designed for use in
clinical trials of interventions to ameliorate cerebral damageaf-
ter acute stroke.1,2 This widely used scale has been recommen-
ded by the Stroke Council of the American Heart Association
for serial assessment of patients with acute stroke.3 Although
often used in studies of neurologic outcome after cardiac sur-
gery,4-6 the NIHSS has never been specifically studied or val-
idated as an appropriate instrument for use in this setting.
The Mini-Mental State Examination (MMSE) is one of
the most widely used instruments for screening for demen-
tia,7,8 particularly for Alzheimer’s disease, and measuring
cognitive change over time in older adults. It is also used
as one of a battery of tests assessing neurocognitive outcome
in studies of patients undergoing cardiac surgery.4,6,9 How-
ever, only 1 study (involving 100 consecutive patients) has
prospectively evaluated the clinical utility of MMSE for
screening in this setting.10 Although the investigators con-
cluded that MMSE-based detection of cognitive dysfunction
should warrant geriatric follow-up after hospital discharge,rdiovascular Surgery c Volume 139, Number 4 901
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CPB ¼ cardiopulmonary bypass
IREF ¼ Ischemia Research and Education
FoundationMMSE ¼ Mini-Mental State Examination
NIHSS ¼ National Institutes of Health Stroke Scale
ROC ¼ receiver operating characteristictheir study was too small to correlate changes on the MMSE
with overt neurologic sequelae.
We have previously described the classification of new
overt adverse neurologic sequelae after cardiac surgery
into 2 general categories: type I (death due to stroke or hyp-
oxic encephalopathy, nonfatal stroke, transient ischemic at-
tack, or stupor or coma at the time of discharge) and type II
(new deterioration in intellectual function, confusion, agita-
tion, disorientation, memory deficit, or seizure without evi-
dence of focal injury).11 Our prior study, however, used
neither the NIHSS nor the MMSE to assess neurologic out-
come.11 In the current study, we wanted to determine
whether postoperative changes from baseline in NIHSS
scores, MMSE scores, or both would be sensitive or specific
to either type I or type II neurologic outcomes. We hypoth-
esized that the NIHSS would be sensitive and specific for
detecting overt new postoperative type I outcomes but less
so for type II outcomes. However, the MMSE, as a single
screening test, might not be sensitive or specific for either
type I or type II neurologic outcomes. To test these hypoth-
eses, we analyzed preoperative and postoperative NIHSS
and MMSE scores that were gathered prospectively in
a large, international, multicenter study.
MATERIALS AND METHODS
Study Design and Patients
The Multicenter Study of Perioperative Ischemia Epidemiology II,
funded by the Ischemia Research and Education Foundation (IREF), is a ret-
rospective analysis of prospectively collected data in patients undergoing
coronary artery bypass grafting (CABG) surgery at 72 hospitals in 17 coun-
tries between November 1996 and June 2000. A systematic sampling
scheme12 was used to select up to 100 patients at each site, aged 18 years
or older, undergoing CABG surgery with or without valve repair or replace-
ment while on cardiopulmonary bypass (CPB). All participating sites in the
study were required to submit their institutional review board approval to
IREF to obtain authorization to join the study. Written informed consent
was obtained from each patient before enrollment could ensue.
Of the 5436 patients enrolled (Figure 1), 371 were excluded from the
data analyses because of patient withdrawal (n ¼ 32), death before surgery
(n ¼ 2), canceled or rescheduled surgery (n ¼ 97), alteration of surgical
schedule (n ¼ 132), enrollment in another study (n ¼ 11), or incomplete
data collection (n ¼ 97; see Appendix 1). Also excluded were 358 patients
who underwent a carotid procedure concurrently with CABG (n ¼ 56), pa-
tients who underwent emergency CABG because of life-threatening condi-
tions (n ¼ 12), patients who had severe hematologic disorders (n ¼ 12),ournal of Thoracic and Cardiovascular Surgpatients who had religious beliefs precluding transfusion (n ¼ 5), patients
who had a previous deforming injury such as amputation (n ¼ 17), and pa-
tients who had a known history of intravenous drug use or alcohol abuse
(n ¼ 271).
Test Administration
Standardized NIHSS certification procedures were followed.13,14 At
each site, all personnel planning to administer the NIHSS received training
and were required to pass a certification test. A standardized NIHSS training
videotape provided demonstration cases and detailed instructions regarding
test procedures and scoring of each scale item. Individuals seeking certifica-
tion then viewed a separate videotape that required completion of the
NIHSS for each of 5 standardized patients. Answers were submitted to
IREF, an organization accredited for certification. The individual seeking
certification was required to have a test score of at least 100 correct answers
of a possible total of 105. Each site was notified of the certification status of
its research personnel. Certification test data for each test giver from each
participating site were stored in the IREF database.
Administration of the MMSE does not require certification. However, all
clinical personnel conducting this examination attended a training session.
Furthermore, each test giver received printed instructions in his/her native
language for each question on the examination.
Data Collection and Management
Data were collected from each patient by independent investigators
throughout each patient’s hospitalization. The collected data included
demographic, historical, clinical, laboratory, electrocardiographic, surgical,
and other intraoperative information, and data regarding adverse outcomes
and resource use. All data fields for each patient were queried for complete-
ness and accuracy, with all changes documented before database closure.
All outcomes were defined in advance and determined by independent
investigators blinded to the study question.
The primary outcome variables were type I or II overt neurologic
sequelae. Type I outcomes were defined as any of the following: death
due to stroke or hypoxic encephalopathy, nonfatal stroke, transient ischemic
attack, or stupor or coma at the time of discharge. Type II outcomes were
defined, according to a ‘‘2-day, 2-item’’ rule, as the presence of 2 or
more indications of intellectual dysfunction (eg, confusion, disorientation,
agitation, memory deficits, or seizures) on 2 or more days, not necessarily
consecutive. All final type I and type II outcomes were determined by com-
mittee. The primary predictor variable for both type I and type II outcomes
was postoperative worsening in NIHSS or MMSE score from the preoper-
ative baseline score. Receiver operating characteristic (ROC) curves were
created and used to determine the predictive value of worsening in NIHSS
or MMSE scores with regard to type I and II outcomes. The sensitivity,
specificity, positive predictive value, negative predictive value, and likeli-
hood ratio of the NIHSS or MMSE score are reported.
The NIHSS and MMSE examinations were routinely performed per the
study protocol on postoperative day 3, 4, or 5 by investigators certified in
administration of these tests. On the NIHSS, a perfect score is zero, each
point on the neurologic deficit scale is assigned a whole number, the max-
imum number of possible points is 42, and higher scores indicate worsening
neurologic function. On the MMSE, a perfect score is 30, each wrong
answer is assigned a point value (ie, a whole number), and lower scores in-
dicate worsening neurocognitive dysfunction. To establish the clinical util-
ity of NIHSS and MMSE scores in prediction of postoperative type I or II
outcomes in cardiac surgical patients, analyses for ROC curve, sensitivity,
and specificity were performed for worsening of score (postoperative score
minus preoperative score).
For missing data regarding potential predictors, a combined variables
approach was used. For missing NIHSS or MMSE scores, most study
patients were examined but had missing records for a few individual ques-
tions; thus, imputation was performed by dividing the patients into 4 groups:
female aged 70 years, male aged 70 years, female aged>70 years, andery c April 2010
5436 Patients were enrolled
32 Withdrew from study before surgery
2 Died before surgery
97 Did not undergo surgery or surgery was rescheduled
132 Did not undergo cardiopulmonary bypass 
11 Were enrolled in another clinical trial
97 Had incomplete data
5065 Patients could be 
evaluated
358 Were excluded for fitting any of the criteria:
Underwent carotid procedure concurrently with CABG (56)
Underwent emergency CABG due to life threatening   
condition (12)
Had severe hematologic disorders (12)
Had religious beliefs precluding transfusion (5)
Had previous deforming injury or surgery  (17)
Had known history of IV drug use or alcohol abuse (271)
4707 Patients in study
FIGURE 1. Consolidated Standards of Reporting Trials diagram of patient enrollment. CABG, Coronary artery bypass grafting.
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the NIHSS or MMSE, stratified by age and gender, separately for the pre-
operative and postoperative periods. Missing data for the individual ques-
tion for each patient were imputed using the mean score of the question
and then sum scores for all questions.
Baseline characteristics, which included demographic, historical, preop-
erative and intraoperative factors, and univariate outcomes, were compared
among patients without type I or II outcome, patients with type I outcome,
and patients with type II outcome (see Appendix 2). The Kruskal–Wallis
test and chi-square test were used for group comparisons among continuous
and categorical variables, respectively.
To assess the independent effects of predictors on ‘‘subnormal’’ (greater
than zero) preoperative or postoperative NIHSS score, a Zero-inflated Neg-
ative binomial model with a random effect of country (the NLMIXED pro-
cedure in SAS software; SAS Institute, Inc, Cary, NC) was used. This will
account for the excess of zeros in NIHSS scores.15 A Logit model with bi-
nomial assumption was used to account for the probability of a zero-NIHSS
score. Then a Negative binomial regression was performed to model the
count outcome in the not-always-zero group. The preoperative subnormal
NIHSS score model was adjusted for baseline characteristics and countries.
The additional adjustments for preoperative NIHSS score and intraoperative
factors were added in the postoperative adverse NIHSS score model.
To evaluate MMSE scores, we defined a ‘‘subnormal’’ MMSE score
according to the score distribution and the analysis ofROCcurve, sensitivity,
and specificity of preoperative or postoperativeMMSE scores with regard to
type I or II outcomes and literature review.16,17 Both preoperative and post-
operative MMSE scores were categorized as ‘‘high score’’ (normal) ¼ 27–
30, ‘‘moderate score’’¼ 24–26, and ‘‘low score’’ (subnormal)¼ 0–23.Gen-
eralized estimating equations regression models for ordinal outcomes (the
GENMOD procedure) were performed to assess the associations between
subnormalMMSE scores and predictors and account for the clustering of pa-
tients within countries. The preoperative subnormalMMSE scoremodelwas
adjusted for baseline characteristics and countries. Additional adjustments
for preoperative MMSE score and intraoperative factors were added in the
postoperative subnormal MMSE score model.The Journal of Thoracic and CaWe developed a series of multivariable models to assess the independent
effects of predictors on the type I or II outcome and stroke (fatal or nonfatal).
Themodels were adjusted for baseline characteristics and intraoperative fac-
tors. Generalized estimating equations models (the GENMOD procedure)
were used to account for the clustering of patients within countries. All anal-
yses were performed with SAS software, version 8.12.RESULTS
Of the 4707 study patients (Table 1), 2.9% (135/4707)
had new postoperative type I outcomes, and 6.4% (301/
4707) had type II outcomes. Resource use, measured by
length of postoperative intensive care unit and hospital stays
and discharge to a facility other than home, was significantly
greater among patients with worse outcomes (Table 1). The
median time of postoperative NIHSS examination was on
the fourth postoperative day. The area under the ROC curve
(AUC) for changes in NIHSS score was 0.89 for type I out-
comes and 0.66 for type II outcomes (Table 2). There was
little change in the AUC when correction factors were
applied for age and higher education (college or postgradu-
ate education) (Table 2).
A 1-point worsening in NIHSS score provided 86%
specificity and 84% sensitivity for type I outcomes, and a 2-
point worsening in theNIHSS score provided 94% specificity
and 71% sensitivity (Table 3). For type II outcomes, a 1-point
worsening in the NIHSS score provided 88% specificity and
44% sensitivity, and a 2-pointworsening in the score provided
95% specificity but only 33% sensitivity (Table 3).
The median time for performance of MMSE examination
was postoperative day 4. The AUC for changes in MMSErdiovascular Surgery c Volume 139, Number 4 903
TABLE 1. Characteristics of study patients (n ¼ 4707)*
Characteristic
All patients
(n ¼ 4707)
Patients without
type I or II outcome
(n ¼ 4271)
Patients with type I
outcome (n ¼ 135)
Patients with type II
outcome (n ¼ 301) P value
Age (y) <.001
Median 64.9 64.1 69.5 71.3
Interquartile range 57.5–71.6 57.0–71.0 63.9–74.3 65.2–75.9
Obesity (BMI>28 kg/m2),
no. (%)
1861 (39.5) 1690 (39.6) 55 (40.7) 116 (38.5) .90
Diabetes, no. (%) 1416 (30.1) 1242 (29.1) 56 (41.5) 118 (39.2) <.001
College or postgraduate
education, no. (%)
850 (18.1) 781 (18.3) 26 (19.3) 43 (14.3) .20
African American,
American Indian, or
Hispanic ethnicity
355 (7.5) 318 (7.4) 11 (8.1) 26 (8.6) .72
Medical history or
preoperative factor, no. (%)
Congestive heart failure 282 (6.0) 224 (5.2) 18 (13.3) 40 (13.3) <.001
Myocardial infarction 2489 (52.9) 2239 (52.4) 74 (54.8) 176 (58.5) .11
Unstable angina 2638 (56.0) 2357 (55.2) 88 (65.2) 193 (64.1) .001
Atrial fibrillation or
atrial flutter
392 (8.3) 331 (7.7) 21 (15.6) 40 (13.3) <.001
Dysrhythmia 891 (18.9) 777 (18.2) 35 (25.9) 79 (26.2) <.001
Neurologic dysfunction 512 (10.9) 420 (9.8) 36 (26.7) 56 (18.7) <.001
Mental dysfunction 717 (15.2) 619 (14.5) 31 (23.0) 67 (22.3) <.001
Hypertension 3284 (69.8) 2933 (68.7) 108 (80.0) 243 (80.7) <.001
Peripheral vascular disease 777 (16.5) 673 (15.8) 31 (23.0) 73 (24.3) <.001
Carotid vascular disease 714 (15.2) 601 (14.1) 38 (28.1) 75 (24.9) <.001
Aortic vascular disease 707 (15.0) 610 (14.3) 28 (20.7) 69 (22.9) <.001
Renal disease 136 (2.9) 106 (2.5) 7 (5.2) 23 (7.6) <.001
Valve disease 910 (19.3) 758 (17.8) 42 (31.1) 110 (36.5) <.001
Pulmonary disease 664 (14.1) 578 (13.5) 30 (22.2) 56 (18.6) .001
Preoperative pulse
pressure, mm Hg
<.001
Median 57.0 56.5 62.5 60.0
Interquartile range 48.0–67.5 48.0–67.0 52.0–76.0 48.0–71.0
Preoperative insertion
of IABP
34 (0.7) 31 (0.7) 0 (0.0) 3 (1.0) .52
Redo operation 311 (6.6) 267 (6.3) 15 (11.1) 29 (9.6) .008
Surgical factor, no. (%)
Concomitant current
procedure
655 (13.9) 541 (12.7) 34 (25.2) 80 (26.6) <.001
Concurrent CABG and
valve (aortic/mitral) surgery
508 (10.8) 419 (9.8) 26 (19.3) 63 (20.9) <.001
Bypass of>3 proximal
aortic anastomoses
191 (4.1) 160 (3.7) 13 (9.6) 18 (6.0) <.001
Intraoperative use of
antifibrinolyticsy
2751 (67.6) 2477 (67.1) 84 (70.6) 190 (74.2) .05
Intraoperative hypertensionz 1678 (36.4) 1478 (35.4) 62 (46.6) 138 (46.5) <.001
Intraoperative atrial
fibrillation or atrial flutter
345 (7.3) 296 (6.9) 18 (13.3) 31 (10.3) .002
Intraoperative homologous
red blood cell transfusion
1767 (37.6) 1525 (35.7) 61 (45.2) 181 (60.1) <.001
Intraoperative homologous
fresh-frozen plasma
transfusion
487 (10.4) 395 (9.3) 27 (20.0) 65 (21.6) <.001
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TABLE 1. Continued
Characteristic
All patients
(n ¼ 4707)
Patients without
type I or II outcome
(n ¼ 4271)
Patients with type I
outcome (n ¼ 135)
Patients with type II
outcome (n ¼ 301) P value
Intraoperative homologous
platelets transfusion
424 (9.0) 346 (8.1) 19 (14.1) 59 (19.6) <.001
Return to CPB 210 (4.5) 175 (4.1) 13 (9.6) 22 (7.3) <.001
Duration of CPB (min) <.001
Median 96.0 94.0 107.0 109.0
Interquartile range 74.0–123.0 73.0–121.0 86.0–136.0 82.0–142.0
Postoperative factor, no. (%)
Postoperative renal compositex 226 (4.8) 145 (3.4) 30 (22.2) 51 (16.9) <.001
Length of ICU stay (d) <.001
Median 1.3 1.2 3.9 4.2
Interquartile range 0.9–2.8 0.9–2.3 1.5–9.3 1.8–8.0
Length of hospital stay (d) <.001
Median 8.0 8.0 13.0 11.0
Interquartile range 6.0–11.0 6.0–10.0 10.0–21.0 8.0–18.0
Discharge to facility
other than home
1533 (33.6) 1321 (31.7) 64 (56.1) 148 (53.4) <.001
Patient died in hospital 151 (3.2) 106 (2.5) 21 (15.6) 24 (8.0) <.001
BMI, Body mass index; IABP, intraaortic balloon pump; ICU, intensive care unit; CABG, coronary artery bypass graft; CPB, cardiopulmonary bypass. *Continuous variables are
summarized by medians and interquartile ranges, and P values were calculated by the Kruskal–Wallis test; categorical variables are summarized by numbers and percentages, and
P values were calculated by the chi-square test. Missing data for patients with neurologic dysfunction: 5 without type I or II outcome and 1 with type II outcome; missing data for
patients with valve disease: 2 without type I or II outcome; missing data for preoperative pulse pressure: 7 without type I or II outcome; missing data for bypass of>3 proximal aortic
anastomoses: 1 without type I or II outcome; missing data for intraoperative use of anti-fibrinolytics: 579 without type I or II outcome, 16 with type I outcome, and 45 with type II
outcome; missing data for intraoperative hypertension: 91 without type I or II outcome, 2 with type I outcome, and 4 with type II outcome; missing data for intraoperative homol-
ogous red blood cell transfusion: 4 without type I or II outcome; missing data for intraoperative fresh-frozen plasma transfusion: 6 without type I or II outcome; missing data for
intraoperative platelets transfusion: 6 without type I or II outcome; missing data for those discharged to facility other than home: 106 without type I or II outcome, 21 with type I
outcome, and 24 with type II outcome. yIntraoperative use of antifibrinolytics was defined as administration of>2,000,000 KIU aprotinin intravenously before the end of surgery,>
10 g aminocaproic acid, or>1 g tranexamic acid. zIntraoperative hypertension was defined as highest systolic blood pressure>160 mm Hg pre-CPB or post-CPB, highest mean
arterial pressure>110 mmHg pre-CPB or during-CPB or post-CPB, or highest systolic blood pressure>160 mmHg after end of protamine infusion, 0–5 min, 6–15 min, or 16–30
min. xPostoperative renal composite was defined as renal dysfunction requiring a postoperative serum creatinine level of at least 177 mmol per liter with an increase over preop-
erative baseline levels of at least 62 mmol per liter or renal failure defined as dysfunction requiring dialysis or in-hospital death with evidence at autopsy of acute renal failure.
TABLE 2. Receiver operating characteristic for worsening in National
Institutes of Health Stroke Scale or Mini-Mental State Examination
scores predicting type I or II outcomes*
Test Adjustment
ROC for
prediction
of type I outcome
ROC for
prediction of
type II outcome
NIHSS Without adjustment 0.89 0.66
NIHSS Adjustment for agey
and educationz
0.89 0.73
MMSE Without adjustment 0.75 0.71
MMSE Adjustment for agey
and educationz
0.75 0.77
ROC, Receiver operating characteristic; NIHSS, National Institutes of Health Stroke
Scale;MMSE,Mini-Mental State Examination. *Type I, event(s) before postoperative
NIHSS test or MMSE test, or type I–neurologic death. yAge, age>60 y and per 5 y
thereof, and>80 y. zEducation, with higher education (college or postgraduate edu-
cation) vs without higher education.
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comes (Table 2). There was little change in the AUC when
correction factors were applied for age and higher education
(college or postgraduate education) (Table 2). A 2-point
worsening in MMSE score provided only 73% specificity
and 63% sensitivity for type I outcomes (Table 3). For
type II outcomes, a 2-point worsening in the MMSE score
provided 73% specificity and 62% sensitivity (Table 3).
For the NIHSS, 37% of patients were tested on postoper-
ative day 3, 30% of patients were tested on postoperative
day 4, and 22% of patients were tested on postoperative
day 5. For the MMSE, 38% of patients were tested on post-
operative day 3, 30% of patients were tested on postopera-
tive day 4, and 22% of patients were tested on postoperative
day 5. There were small, statistically significant but clini-
cally unimportant differences in the NIHSS and MMSE
results according to the postoperative date of testing (on
postoperative day 3, 4, or 5). These differences are reported
in Appendices 3 and 4.
We also examined the predictive value of both the NIHSS
andMMSE if only nonfatal or fatal stroke outcomes are con-
sidered. The sensitivity and specificity of both the NIHSS
and MMSE were better for stroke only (Table 4). TheThe Journal of Thoracic and CaAUC for changes in NIHSS score was 0.95, and the AUC
for changes in MMSE score was 0.77.
Multivariate analysis determined that the common predic-
tors of worsening postoperative NIHSS and MMSE scores
included age increment, performance on the preoperative
NIHSS and MMSE, a history of neurologic dysfunction,rdiovascular Surgery c Volume 139, Number 4 905
TABLE 3. Sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratio of National Institutes of Health Stroke
Scale or Mini-Mental State Examination score for type I or II outcomes
CNS type I or
II outcome
Worsening in
NIHSS or
MMSE score
ROC
curves Specificity Sensitivity
Positive
predictive value
Negative
predictive value
Likelihood
ratio–positive
test result
Likelihood
ratio–negative
test result
Type I* NIHSS change 1 0.85 0.86 0.84 0.10 1.00 6.20 0.19
Type I* NIHSS change 2 0.83 0.94 0.71 0.19 0.99 12.79 0.30
Type I* NIHSS change 3 0.75 0.97 0.54 0.25 0.99 18.22 0.48
Type I* NIHSS change 4 0.74 0.98 0.49 0.35 0.99 28.85 0.52
Type II NIHSS change 1 0.66 0.88 0.44 0.19 0.96 3.66 0.63
Type II NIHSS change 2 0.64 0.95 0.33 0.31 0.96 6.95 0.70
Type II NIHSS change 3 0.61 0.98 0.24 0.38 0.95 9.84 0.78
Type II NIHSS change 4 0.57 0.98 0.16 0.38 0.95 9.60 0.86
Type I* MMSE change 1 0.66 0.54 0.79 0.03 0.99 1.71 0.39
Type I* MMSE change 2 0.68 0.73 0.63 0.05 0.99 2.29 0.51
Type I* MMSE change 3 0.69 0.84 0.54 0.06 0.99 3.30 0.55
Type I* MMSE change 4 0.69 0.90 0.48 0.09 0.99 4.84 0.57
Type II MMSE change 1 0.65 0.54 0.75 0.10 0.97 1.63 0.46
Type II MMSE change 2 0.68 0.73 0.62 0.14 0.97 2.35 0.51
Type II MMSE change 3 0.66 0.85 0.48 0.18 0.96 3.18 0.62
Type II MMSE change 4 0.65 0.91 0.39 0.23 0.96 4.48 0.67
CNS, Central nervous system; NIHSS,National Institutes of Health Stroke Scale; ROC, receiver operating characteristic;MMSE,Mini-Mental State Examination. *Type I, event(s)
before postoperative NIHSS test or MMSE test, or type I–neurologic death.
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duration of CPB (Table 5). For the NIHSS, additional pre-
dictors of worsening score included congestive heart failure,
hypertension, and pulmonary disease. For the MMSE, addi-
tional predictors of worsening score included female gender,
a history of renal disease, valvular heart disease, and intra-
operative hypertension, whereas higher education was
‘‘protective.’’
In regard to the predictors of type I and type II outcomes,
multivariate analysis determined that the common predictors
of these overt adverse events were age increment, diabetes,
and intraoperative fresh-frozen plasma transfusion (Table
5). For type I outcomes, additional predictors included neu-
rologic dysfunction, congestive heart failure, high pulse pres-
sure, and more than 3 proximal aortic anastomoses. For type
II outcomes, additional predictors included a history of myo-TABLE 4. Sensitivity, specificity, positive predictive value, negative predic
Scale or Mini-Mental State Examination Score for nonfatal or fatal stroke
Worsening in NIHSS
or MMSE score
ROC*
curves Specificity Sensitivity
Positiv
predictive
NIHSS change 1 0.91 0.86 0.95 0.09
NIHSS change 2 0.88 0.94 0.82 0.17
NIHSS change 3 0.80 0.97 0.63 0.23
NIHSS change 4 0.78 0.98 0.58 0.32
MMSE change 1 0.68 0.54 0.83 0.03
MMSE change 2 0.70 0.73 0.67 0.04
MMSE change 3 0.70 0.84 0.57 0.05
MMSE change 4 0.71 0.90 0.53 0.08
NIHSS, National Institutes of Health Stroke Scale; MMSE, Mini-Mental State Examination
NIHSS test or MMSE test.
906 The Journal of Thoracic and Cardiovascular Surgcardial infarction, renal disease, or valvular heart disease, as
well as intraoperative hypertension and intraoperative trans-
fusion of red blood cells. If only nonfatal or fatal stroke out-
comes are considered, multivariate analysis confirmed that
preoperative predictors were neurologic dysfunction, carotid
disease, pulmonary disease, high pulse pressure, and redo
surgery (Table 6).
The median preoperative NIHSS score was zero (zero
being a perfect score) with an interquartile range of 0 to 0;
85% of study patients had a preoperative NIHSS score of
zero. The median preoperative MMSE score was 29 (30
being a perfect score) with an interquartile range of 27 to
30. Common preoperative predictors of ‘‘poor’’ preopera-
tive NIHSS (Figure 2, A) or MMSE (Figure 2, B) scores
were age increment, congestive heart failure, and valvular
heart disease. For the NIHSS, additional preoperativetive value, and likelihood ratio of National Institutes of Health Stroke
(n ¼ 92 patients)
e
value
Negative
predictive value
Likelihood ratio–
positive test result
Likelihood ratio–
negative test result
1.00 6.96 0.06
1.00 14.38 0.19
0.99 20.49 0.38
0.99 32.44 0.43
0.99 1.79 0.32
0.99 2.44 0.45
0.99 3.47 0.51
0.99 5.20 0.52
; ROC, receiver operating characteristic. *Nonfatal stroke, stroke before postoperative
ery c April 2010
TABLE 5. Model-adjusted ratios for type I or type II cerebral outcome, or worsening National Institutes of Health Stroke Scale or Mini-Mental
State Examination scores associated with selected factors*
Type I CNS
outcome
Type II
CNS outcome
Postoperative
NIHSS Scorey
Postoperative
MMSE scorez
Predictor Logit portion
Negative
binomial portion
OR (95% CI) OR (95% CI) OR (95% CI) RR (95% CI) OR (95% CI)
Age>60 y and per 5 y thereof
and>80 y
1.27 (1.14–1.41){ 1.43 (1.34–1.53){ 0.84 (0.76–0.92){ 1.17 (1.11–1.24){ 1.29 (1.21–1.38){
College or postgraduate education 0.68 (0.55–0.83){
Women 1.24 (1.08–1.43)
Medical history/preoperative factor
Preoperative NIHSS/MMSE score 1.20 (1.13–1.27){ 1.51 (1.45–1.58){
Neurologic dysfunction 2.38 (1.58–3.58){ 1.54 (1.25–1.89){ 1.32 (1.10–1.59)
Congestive heart failure 2.03 (1.00–4.10) 1.33 (1.02–1.74)
Myocardial infarction 1.42 (1.12–1.78)
Hypertension 1.43 (1.17–1.76){
Pulse pressure (per 10 mm Hg
increment)x
1.17 (1.05–1.30)
Pulmonary disease 1.52 (1.23–1.88){
Diabetes 1.54 (1.17–2.04) 1.48 (1.18–1.85){ 1.42 (1.18–1.69){ 1.25 (1.14–1.38){
Renal disease 2.20 (1.12–4.32) 1.74 (1.31–2.32){
Intraoperative factors
>3 proximal aortic anastomoses 2.43 (1.41–4.17)
Valvular heart disease 1.77 (1.40–2.24){ 1.29 (1.15–1.44){
Intraoperative hypertensionk 1.36 (1.17–1.59){ 1.17 (1.03–1.32)
Intraoperative homologous RBC
transfusion
1.48 (1.14–1.92) 1.36 (1.12–1.64) 1.34 (1.14–1.56){
Intraoperative homologous FFP
transfusion
1.99 (1.54–2.58){ 1.54 (1.14–2.09)
CPB time per 30-min increment 0.87 (0.78–0.97) 1.06 (1.001–1.13) 1.15 (1.09–1.22){
CNS, Central nervous system; NIHSS, National Institutes of Health Stroke Scale; MMSE, Mini-Mental State Examination; OR, odds ratio; CI, confidence interval; RR, rate ratio;
RBC, red blood cells; FFP, fresh-frozen plasma; CPB, cardiopulmonary bypass. *Models were adjusted for the patients’ demographic characteristics, medical history, preoperative
or intraoperative factors, and countries.yZero-inflated Negative binomial model is used to assess the association between postoperative NIHSS score and predictors; a Logit model is
used to model the probability of zero-NIHSS score, and then a Negative binomial model is performed to model count outcomes in the not-always-zero group. Rate ratio for pre-
operative NIHSS score was calculated per 1 unit increase. zGeneralized estimating equations model for ordinal outcome is used to assess the association of worsening postoperative
MMSE score and predictors; postoperative MMSE score is categorized as high (27–30), moderate (24–26), and low (<24). Odds ratio for preoperative MMSE score was calculated
as per 1 unit decrease. xPulse pressure per 10 mm Hg increment above a threshold of 40 mm Hg. kIntraoperative hypertension was defined as highest systolic blood pressure>160
mm Hg pre-CPB or post-CPB, highest mean arterial pressure>110 mm Hg pre-CPB or during-CPB or post-CPB, or highest systolic blood pressure>160 mm Hg after end of
protamine infusion 0–5 min, 6–15 min, or 16–30 min. {P value< .001.
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Dpredictors of a ‘‘poor’’ score were a history of neurologic
dysfunction and renal disease. For the MMSE, additional
preoperative predictors of a ‘‘poor’’ score were a history
of mental dysfunction, unstable angina, and peripheral vas-
cular disease, whereas higher education was ‘‘protective.’’
DISCUSSION
We have reported preoperative and postoperative NIHSS
and MMSE scores in a large international sample of patients
undergoing cardiac surgery with CPB and the relationship of
these scores to type I and II neurologic sequelae of surgery.
Our findings provide the only reference for evaluating
changes in NIHSS or MMSE scores from baseline, when
these tests are used in clinical trials designed to diagnose,
mitigate, or treat adverse neurologic outcome after cardiac
surgery. We also defined predictors for type I and II adverseThe Journal of Thoracic and Caneurologic outcomes and compared these with predictors for
postoperative worsening in NIHSS and MMSE scores.
Finally, we explored patient characteristics that predict pre-
operative subnormal NIHSS and MMSE scores.
The NIHSS is a reliable2,13,14 and validated1,18,19 measure
of stroke-related neurologic impairment. It measures several
aspects of brain function, including consciousness, vision,
sensation, movement, speech, and language, with a maximal
score of 42 representing the most severe and devastating
stroke. A normal score is zero (no stroke), a score of 1 to
4 indicates a minor stroke, a score of 5 to 15 indicates a mod-
erate stroke, a score of 15 to 20 indicates a moderate-to-se-
vere stroke, and a score of 21 to 42 indicates a severe
stroke.20 The NIHSS is frequently used in therapeutic trials
of stroke rehabilitation as the primary serial measure of the
efficacy of interventions designed to ameliorate sequelaerdiovascular Surgery c Volume 139, Number 4 907
TABLE 6. Model-adjusted odds ratios for nonfatal or fatal stroke
(n ¼ 92 patients) associated with preoperative risk factors*
Predictor OR (95% CI) P value
Medical history/preoperative factor
Neurologic dysfunction 1.81 (1.35–2.42) <.001
Carotid disease 1.75 (1.07–2.87) .03
Pulmonary disease 2.11 (1.15–3.88) .02
Pulse pressure (per 10 mm Hg
increment)y
1.36 (1.25–1.48) <.001
Redo surgeryz 2.47 (1.50–4.08) <.001
OR, Odds ratio; CI, confidence interval. *Excluded were 13 patients with missing
values for at least one of the risk factors in the model, including the covariates. yPulse
pressure per 10 mm Hg increment above a threshold of 40 mm Hg. zRedo surgery was
defined as with previous CABG, valve, cardiac, noncardiac, or bypass graft surgery.
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Dafter documented stroke.21-23 It is often chosen for its sim-
plicity of administration, its high reproducibility of results
among allied health personnel, and the ease with which
results can be transformed for database collection and statis-
tical analysis. Although previously used in the setting of car-10.5
Predictor
Age over 60 per 5yr thereof and over 80
Neurologic dysfunction
Congestive heart failure
Valvular heart disease
Renal disease
0.17 0.2 0.25 0.3
Predictor
Age over 60 per 5yr thereof and over 80
College or postgraduate education
Mental dysfunction
Unstable angina
Congestive heart failure
Valvular heart disease
Peripheral vascular disease
B
A
FIGURE 2. Multivariable predictors of adverse preoperative NIHSS or MMSE
score. A Logit model with binomial assumption is used to determine whether a
group, and then a Negative binomial model for count data is performed to mode
ment is related to NIHSS score of zero with a 30% decrease in odds (OR¼ 0.70;
(OR¼ 3.56; 95%CI, 1.57–8.05, P¼ .003). For the Negative binomial portion, ag
disease, and renal disease increase the risk of increasing NIHSS score (adverse NI
analysis for preoperativeMMSE score. MMSE score was categorized as high (27
unstable angina, congestive heart failure, valvular heart disease, and peripheral va
MMSE score); higher education decreases the risk of adverse MMSE score. Cou
ratio; RR, rate ratio; CI, confidence interval.
908 The Journal of Thoracic and Cardiovascular Surgdiac surgery to screen for postoperative neurologic changes
in patients with and without suspected acute stroke,4-6 the
NIHSS had not been previously validated as a tool for diag-
nosing and quantifying the degree of neurologic injury
(or lack thereof) in this setting. Our findings indicate that
postoperative worsening of the NIHSS score is an excellent
predictor of type I outcome after CABG surgery.
The MMSE is a brief, standardized, and validated instru-
ment that was originally used to screen for Alzheimer’s dis-
ease and is now also used to screen for dementia.7,8,24 It is
commonly used in both clinical and research settings to mea-
sure cognitive impairment in various disease states, docu-
ment intellectual changes over time, and assess the effects
of potential therapeutic agents on cognitive function. The
MMSE is attractive because it is brief, easily administered,
and easily scored. Estimates of internal consistency25 and in-
terrater reliability7,26 are good. Premorbid intelligence and
educational attainment affect MMSE scores, in that less
intelligent or less educated individuals tend to score lower2 3 4
RR (95% CI)    P Value
1.09 (1.01 – 1.17)      .03
2.48 (1.85 – 3.33)    <.001
2.48 (1.70 – 3.61)    <.001
1.34 (1.04 – 1.72)      .02
1.98 (1.24 – 3.15)      .005
1 2 30.4 0.5
OR (95% CI)    P Value
1.33 (1.26 – 1.40)    <.001
0.25 (0.20 – 0.31)    <.001
1.50 (1.25 – 1.80)    <.001
1.37 (1.12 – 1.67)      .002
1.58 (1.03 – 2.42)      .03
1.30 (1.16 – 1.46)    <.001
1.23 (1.08 – 1.41)      .002
scores. A, Zero-inflated Negative binomial model for preoperative NIHSS
n individual count outcome is from the always-zero or the not-always-zero
l outcomes in the not-always-zero group. For the logistic portion, age incre-
95%CI, 0.55–0.91, P¼ .008); higher education increases the odds to 3-fold
e increment, neurologic dysfunction, congestive heart failure, valvular heart
HSS score). B, Generalized estimating equations model for ordinal outcome
–30), moderate (24–26), and low (<24). Age increment, mental dysfunction,
scular disease increase the risk of decreasingMMSE score category (adverse
ntry was adjusted for in both NIHSS (A) and MMSE (B) models. OR, Odds
ery c April 2010
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individuals.17,25,27 Also, MMSE scores decrease with
advancing age, from a median score of 29 at 18 to 24 years
of age to a median of 25 at 80 years of age.24,27 Although
the MMSE has been used in the setting of cardiac surgery to
measure cognitive change in patients with and without sus-
pected changes in intellectual function,4,6,9 the preoperative
and postoperative clinical utility of MMSE scores has not
been published for a large population of surgical patients
of any type. Our patients scored relatively well on this test
in the preoperative period (median MMSE score of 29
with an interquartile range of 27–30.). Not unexpectedly,
we have confirmed that preoperative MMSE scores are
related to age and education. Our findings indicate that
postoperative worsening of the MMSE score provides only
fair discrimination for type I or II outcomes after CABG
surgery.
Common predictors of deterioration in NIHSS or MMSE
and overt type I or II adverse outcomes included older age,
a history of neurologic dysfunction (due to stroke or tran-
sient ischemic attack), and diabetes, as well as intraoperative
red blood cell transfusion and duration of CPB. These risk
factors have been identified as being associated with adverse
neurologic outcome.11,28-32 If only nonfatal or fatal stroke
outcomes are considered, multivariate analysis confirmed
some of the same preoperative predictors, notably a history
of neurologic dysfunction. These findings may have clinical
implications, in that perhaps patients with a known history of
stroke or transient ischemic attack should undergo myocar-
dial revascularization in hospitals having immediately avail-
able services for the treatment of acute stroke.32
In our previous study,11 completed in 1993, we did not
formally assess neurologic function with any recognized
scale or scoring system in either the preoperative or postop-
erative periods. In both the previous and the current study,
individual investigators at each site assessed type I deficits
or type II dysfunction in whatever manner they deemed clin-
ically suitable. Notably, the incidence of type I outcomes in
the present study was similar to that in our previous study
(2.9% vs 3.1%), whereas the incidence of type II outcomes
was somewhat higher in the present study (6.4% vs
3.0%).11 This may be because patients in the current era
are older and more likely to have mild preoperative or post-
operative cognitive deficits, although, fortunately, advances
in cardiac surgical techniques and extracorporeal circulation
technology have prevented increases in the incidence of
frank stroke.5
As in our previous study,11 we examined conservative
measures of resource use, namely, the duration of intensive
care, the total duration of the hospital stay after surgery, and
the rate of discharge to intermediate- or long-term care facil-
ities. All 3 measures were markedly prolonged for patients
with either type I or type II adverse neurologic outcomes.
Compared with patients without adverse neurologic out-The Journal of Thoracic and Cacomes, patients with type I outcome stayed an additional
21/2 days in the intensive care unit and an additional 5
days on the ward, suggesting that regardless of institutional
practice, substantial resources are consumed by such
patients. Furthermore, compared with patients without ad-
verse neurologic outcomes, patients with type II outcomes
stayed an additional 3 days in the intensive care unit and 3
days on the ward. (These data are included in Table 1.) On
the basis of conservative estimates of boarding charges of
approximately $3700 per day in an intensive care unit and
$1700 per day on a ward, type I neurologic events are
responsible for approximately $18,000 in additional costs
per patient in in-hospital boarding costs, and type II events
are responsible for approximately $16,000 in additional
costs per patient. Furthermore, the costs of changes in dis-
charge planning and long-term out-of-hospital medical and
rehabilitative services undoubtedly result in considerable
additional expenditure.
Study Limitations
Several limitations of the present study may affect the
generalizability and utility of its findings. The data are
approximately 10 years old, and the patients were only at
moderate risk for adverse outcomes. Although overt neuro-
logic adverse events were a relatively small percentage of
the total, our incidence of type I outcome (2.9%) is not dis-
similar from other more recent series.29-31 As in our previous
study,11 although data were collected prospectively, the
study is limited by its purely observational design. The study
was conducted with data collected from medical centers
throughout the world, a diversity that is both a strength and
a potential weakness. The assessments were made by multi-
ple investigators who were not neurologists, and the
assessments were not always made by the same investigator
within an institution. Furthermore, we were not able to con-
sistently obtain objective evidence of acute cerebral ischemic
events (eg, computed tomography ormagnetic resonance im-
aging scans) in the postoperative period. In addition, only
87.2% of patients (4105 of 4707) completed the preoperative
and postoperative NIHSS tests, and even fewer completed
the MMSE test (2868 of 4707 [60.9%]). Finally, a complete
battery of neurocognitive tests were not administered, only
the MMSE. In the absence of more extensive evaluation of
neurocognitive dysfunction, we did attempt to be rigorous
in identifying type II outcomes, mandating that 2 or more in-
dications of ‘‘intellectual dysfunction’’ be present on 2 or
more days of a patient’s hospitalization.
Despite these limitations, our current findings warrant
additional investigations. Future studies should examine
the long-term outcomes associated with unexpected postop-
erative worsening of either test score. Outcomes of interest
would include worsening in patient scores several years after
surgery33; ability to return to employment; functional out-
comes as measured by quality of life assessment tools;rdiovascular Surgery c Volume 139, Number 4 909
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Dneed for rehospitalization; and postdischarge morbidity due
to depression, late stroke, or death.
CONCLUSIONS
Standardized scores on the NIHSS and MMSE tests are
used for the quantitative assessment of adverse neurologic
events after cardiac surgery. We have provided a reference
defining the clinical utility of assessment of baseline scores
and postoperative worsening in scores on these tests, which
will be useful in the evaluation of results of clinical trials
designed to diagnose, mitigate, or treat adverse neurologic
outcomes after cardiac surgery.
The authors are indebted to Stephen N. Palmer, PhD, ELS, for
editorial support.
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Appendix 1.
The IREF is an independent nonprofit foundation, formed in
1987, that develops clinical investigators via observational
studies and clinical trials addressing ischemic injury of the
heart, brain, kidney, and gastrointestinal tract. The IREF
provided all funding for execution of the study, collection
of the data, and analysis and publication of the findings.
The Multicenter Study of Perioperative Ischemia Research
Group, formed in 1988, is an association of 160 international
medical centers located in 23 countries organized through
and supported by grants from the IREF.
The following institutions and persons coordinated the
Multicenter Study of Perioperative Ischemia Research
Group EPI-II study. Study Chairman—D. Mangano; Senior
Editors—J. Levin, L. Saidman; Study Design and Analysis
Center: Ischemia Research and Education Foundation—
P. Barash, C. Dietzel, A. Herskowitz, K. Huang, Y. Miao,
I. C. Tudor, S. Wang, Y. Weng; Editorial/Administrative
Group—D. Beatty, I. Lei, B. Xavier.
The following institutions and persons participated in the
McSPI EPI-II Study. Centers and investigators: United
States—University of Chicago, Weiss Memorial Hospi-
tal—S. Aronson; Beth Israel Hospital—M. Comunale; Mas-
sachusetts General—M. D’Ambra; University of Rochester
— M. Eaton; Baystate Medical Center—R. Engelman;
Baylor College of Medicine—J. Fitch; Duke Medical
Center—K. Grichnik; UTHSCSA-Audie Murphy VA,
UTHSCSA-University Hospital—C. B. Hantler; St. Luke’s
Roosevelt Hospital—Z. Hillel; New York University Medi-
cal Center—M. Kanchuger, J. Ostrowski; Stanford Univer-
sity Medical Center—C. M. Mangano; Yale University
School of Medicine—J. Mathew, M. Fontes, P. Barash; Uni-
versity of Wisconsin—M. McSweeney, R. Wolman; Uni-
versity of Arkansas for Medical Sciences—C. A.
Napolitano; Discovery Alliance, Inc.—L. A. Nesbitt; VA
Medical Center, Milwaukee—N. Nijhawan; Texas Heart In-
stitute, Mercy Medical Center—N. Nussmeier; University
of Texas Medical School, Houston—E. G. Pivalizza; Uni-
versity of Arizona—S. Polson; Emory University Hospi-
tal—J. Ramsay; Kaiser Foundation Hospital—G. Roach;
Thomas Jefferson University Hospital, MCP Hahnemann
University Hospital— N. Schwann; VAMC Houston—S.
Shenaq; Maimonides Medical Center—K. Shevde; Mt.
Sinai Medical Center—L. Shore-Lesserson, D. Bronheim;
University of Michigan—J. Wahr; University of Washing-
ton—B. Spiess, I. Wright; VA Medical Center, S. F.—A.
Wallace; Austria—University of Graz—H. Metzler; Can-
ada—University of British Columbia—D. Ansley, J. P.
O’Connor; The Toronto Hospital—D. Cheng; Laval Hospi-
tal, Quebec—D. Coˆte; Health Sciences Centre-University of
Manitoba—P. Duke; University of Ottawa Heart Institute—
J. Y. Dupuis, M. Hynes; University of Alberta Hospital—B.
Finegan; Montreal Heart Institute—R. Martineau, P. Cou-
ture; St. Michael’s Hospital, University of Toronto—D. Ma-
zer; Colombia—Fundacion Clinico Shaio—J. C. Villalba,
M. E. Colmenares; France—CHRU Le Bocage—C. Girard;
Hospital Pasteur—C. Isetta; Germany—Universita¨t
Wrzburg—C. A. Greim, N. Roewer; Universita¨t Bonn—
A. Hoeft; University of Halle—R. Loeb, J. Radke; Westfa-
lischeWilhelms-Universita¨t Munster—T. Mollhoff; Univer-
sita¨t Heidelberg—J. Motsch, E. Martin; Ludwig-
Maximillians Universita¨t—E. Ott; Universita¨t Krankenhaus
Eppendorf—J. Scholz, P.Tonner; Georg-August Universita¨t
Go¨ttingen—H. Sonntag; Ludwig-Maximillians Universita¨t
(Department of Cardiac Surgery)—P. Ueberfuhr; Hun-
gary—Orszagos Kardiologiai Intezet—A. Szekely; India—
Escorts Heart Institute—R. Juneja; Apollo Hospital—G.
Mani; Israel—Hadassah University Hospital—B. Drenger, Y.
Gozal, E. Elami; Italy—San Raffaele Hospital, Universita de
Milano—C. Tommasino; Mexico—Instituto Nacional de
Cardiologia—P. Luna; The Netherlands—University Hospi-
tal Maastricht—P. Roekaerts, S. DeLange; Poland—Institute
of Cardiology—R. Pfitzner; Romania—Institute of Cardiol-
ogy—D. Filipescu; Thailand—Siriraj Hospital—U. Prakan-
rattana; United Kingdom—Glenfield Hospital—D. J. R.
Duthie; St. Thomas’ Hospital—R. O. Feneck; The Cardiotho-
racic Centre, Liverpool—M. A. Fox; South Cleveland Hospi-
tal—J. D. Park; Southampton General Hospital—D. Smith;
Manchester Royal Infirmary—A. Vohra; Papworth Hospi-
tal— A. Vuylsteke, R. D. Latimer.
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DAppendix 2. Demographic characteristics
Age, or age>60 y and per 5 y thereof and>80 y
Gender
Obesity (BMI>28)
Regular or current smoke
College or postgraduate education
Race or ethnicity
Medical history or preoperative factors
Stroke
TIA
Preoperative neurologic dysfunction (history of stroke or TIA)
Preoperative mental dysfunction
Myocardial infarction
Unstable angina
Congestive heart failure
Hypertension
Pulse pressure
Controlled hypertension
Uncontrolled hypertension
Atrial fibrillation/atrial flutter
Dysrhythmia
Tachyarrhythmias
Cardiomegaly abnormality (preoperative chest x-ray)
Valvular stenosis
Valvular insufficiency
rdiovascular Surgery c Volume 139, Number 4 911
Appendix 2. Continued
Preoperative valve (aortic/mitral) calcification: chest x-ray/cardiac
catheterization
Any valve (aortic/mitral) disease (stenosis/insufficiency/calcification) on
admission or
Preoperation
Redo surgery
Preoperative IABP
Preoperative aortic vascular disease
Peripheral vascular disease
Carotid vascular disease
Pulmonary disease
Diabetes
Renal disease
Liver disease
Hematologic disorder
Previous carotid endarterectomy
Intraoperative and surgical factors
Concurrent combined surgery
Bypass of>3 proximal aortic anastomoses
Appendix 2. Continued
Aortic vascular disease (history or preoperative or intraoperative image/
palpation)
All vascular disease, carotid vascular disease, peripheral vascular disease, or
aortic vascular disease (history, preoperative, or intraoperative image/
palpation)
Valve stenosis (history, preoperative, or prebypass)
Valve insufficiency (history, preoperative, or prebypass)
Valvular calcification (preoperative or intraoperative)
Any valve (aortic/mitral) disease (stenosis/insufficiency/calcification)
(on admission or preoperative or intraoperative)
Intraoperative hypertension
Intraoperative atrial fibrillation/atrial flutter
Intraoperative homologous red blood cell transfusion
Intraoperative homologous fresh-frozen plasma transfusion
Intraoperative homologous platelets transfusion
Return to CPB
CPB time (min)
BMI, Body mass index; TIA, transient ischemic attack; IABP, intraaortic balloon
pump; CPB, cardiopulmonary bypass.
Appendix 3. Receiver operating characteristic curves, sensitivity, and specificity of National Institutes of Health Stroke Scale score by
postoperative day of National Institutes of Health Stroke Scale test
CNS type I* outcome POD of NIHSS test Test of NIHSS ROC curve Specificity Sensitivity
Type I POD3 NIHSS change 1 0.87 0.88 0.86
Type I POD3 NIHSS change 2 0.79 0.96 0.62
Type I POD3 NIHSS change 3 0.75 0.98 0.52
Type I POD3 NIHSS change 4 0.73 0.98 0.48
Type I POD4 NIHSS change 1 0.82 0.88 0.76
Type I POD4 NIHSS change 2 0.80 0.95 0.65
Type I POD4 NIHSS change 3 0.72 0.98 0.47
Type I POD4 NIHSS change 4 0.70 0.99 0.41
Type I POD5 NIHSS change 1 0.84 0.85 0.83
Type I POD5 NIHSS change 2 0.84 0.93 0.75
Type I POD5 NIHSS change 3 0.77 0.96 0.58
Type I POD5 NIHSS change 4 0.78 0.98 0.58
CNS, Central nervous system; POD, postoperative day; NIHSS, National Institutes of Health Stroke Scale; ROC, receiver operating characteristic. *Type I, event(s) before post-
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Doperative NIHSS test or MMSE test, or type I–neurologic death.Appendix 4. Receiver operating characteristic curves, sensitivity, and specificity of Mini-Mental State Examination score by postoperative day of
Mini-Mental State Examination test
CNS type I* outcome POD of MMSE Test Test of NIHSS ROC curve Specificity Sensitivity
Type I POD3 MMSE change 1 0.61 0.55 0.67
Type I POD3 MMSE change 2 0.64 0.73 0.54
Type I POD3 MMSE change 3 0.67 0.84 0.50
Type I POD3 MMSE change 4 0.68 0.91 0.46
Type I POD4 MMSE change 1 0.68 0.56 0.80
Type I POD4 MMSE change 2 0.65 0.75 0.55
Type I POD4 MMSE change 3 0.65 0.85 0.45
Type I POD4 MMSE change 4 0.63 0.91 0.35
Type I POD5 MMSE change 1 0.72 0.53 0.92
Type I POD5 MMSE change 2 0.72 0.72 0.71
Type I POD5 MMSE change 3 0.75 0.83 0.67
Type I POD5 MMSE change 4 0.76 0.89 0.63
CNS, Central nervous system; ROC, receiver operating characteristic; POD, postoperative day; NIHSS, National Institutes of Health Stroke Scale; MMSE, Mini-Mental State
Examination. *Type I, event(s) before postoperative NIHSS test or MMSE test, or type I–neurologic death.
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